The United States Patent and Trademark Office (USPTO) has issued a key patent no. 8,440,703 (the ‘703 patent) to Acorda Therapeutics. The key patent entitled “Methods of Using Sustained Release Aminopyridine Compositions.” The ‘703 patent includes claims directed to methods of improving lower extremity function and walking and increasing walking speed in patients with multiple sclerosis (MS) by administering less than 15 mg of sustained release 4-aminopyridine (dalfampridine) twice daily.

The ‘703 patent is set to expire in 2025. This patent is eligible for listing in the US Food and Drug Administration (FDA) Orange Book.

The ‘703 patent is separate from the two Ampyra method of use patents issued by the USPTO in 2011 and 2013 that are set to expire in 2027 and 2026, respectively.

Ampyra is approved in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. Ampyra is known as prolonged-, modified-, or sustained-release fampridine (Fampyra) in some countries outside the United States.

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.